DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
« Back to Dashboard
Desvenlafaxine succinateis the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic Pharms Ltd, Hikma, Intellipharmaceutics, Lupin Ltd, Mylan, Rubicon, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in eleven NDAs. There are two patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.
Desvenlafaxine succinate has sixty-eight patent family members in thirty-two countries.
There are sixteen drug master file entries for desvenlafaxine succinate. Seventeen suppliers are listed for this compound.
Summary for DESVENLAFAXINE SUCCINATE
|Drug Master File Entries:||16|
|Finished Product Suppliers / Packagers:||17|
|Raw Ingredient (Bulk) Api Vendors:||31|
|Formulation / Manufacturing:||see details|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for DESVENLAFAXINE SUCCINATE|
|What excipients (inactive ingredients) are in DESVENLAFAXINE SUCCINATE?||DESVENLAFAXINE SUCCINATE excipients list|
|DailyMed Link:||DESVENLAFAXINE SUCCINATE at DailyMed|
Recent Clinical Trials for DESVENLAFAXINE SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||Phase 3|
|Korea Cancer Center Hospital||Phase 4|
|Seoul National University Bundang Hospital||Phase 4|
Pharmacology for DESVENLAFAXINE SUCCINATE
|Drug Class||Serotonin and Norepinephrine Reuptake Inhibitor |
|Mechanism of Action||Norepinephrine Uptake Inhibitors |
Serotonin Uptake Inhibitors
Cytochrome P450 2D6 Inhibitors
Medical Subject Heading (MeSH) Categories for DESVENLAFAXINE SUCCINATE
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Mylan||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||204095-001||Jun 29, 2015||DISCN||No||No||⤷ Free Forever Trial||⤷ Free Forever Trial||⤷ Free Forever Trial|
|Mylan||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||204095-002||Jun 29, 2015||DISCN||No||No||⤷ Free Forever Trial||⤷ Free Forever Trial||⤷ Free Forever Trial|
|Alembic Pharms Ltd||DESVENLAFAXINE SUCCINATE||desvenlafaxine succinate||TABLET, EXTENDED RELEASE;ORAL||204003-003||Sep 14, 2018||AB||RX||No||No||⤷ Free Forever Trial||⤷ Free Forever Trial||⤷ Free Forever Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.